SIGA Technologies, Inc.
ST-246 (tecovirimat monohydrate) SUSPENSION FORMULATIONS
Last updated:
Abstract:
The present invention is directed to a dry suspension for reconstitution containing Tecovirimat (ST-246) powder and simethicone. The dry suspension is dispersed in water to provide an aqueous pharmaceutical suspension formulation for oral administration for treating orthopoxvirus infections and/or eczema vaccinatum. The suspension formulation exhibits excellent stability and good dissolution and has an improved taste and texture.
Status:
Application
Type:
Utility
Filling date:
15 Feb 2017
Issue date:
15 Jul 2021